Related Experiment Video
Updated: Jun 21, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
HCV NS5B polymerase inhibitors
James R Burton1, Gregory T Everson
1Department of Medicine, Division of Gastroenterology and Hepatology, University of Colorado, Denver, Aurora, CO 80045, USA. james.burton@ucdenver.edu
Abstract:
Chronic hepatitis C virus (HCV) infection affects approximately 4 million persons and is the major indication for liver transplantation in the United States. The current standard for treatment of HCV is pegylated interferon in combination with ribavirin. Despite significant advances in treatment, only approximately 50% of patients of treated patients clear HCV infection. Polymerase inhibitors, given their potent antiviral effects, represent a major contribution to the future of HCV treatment. Whether these new drugs will have a role in the treatment of the difficult patient (non-responders, those co-infected with HIV, decompensated liver disease and liver transplant recipients) remains to be determined.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly
Hepatitis
Inhibitors of Bacterial DNA Synthesis
